Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
72 studies found for:    Open Studies | "Vitamin K"
Show Display Options
Rank Status Study
21 Recruiting Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD
Condition: Cervical Artery Dissection
Interventions: Drug: Acetylsalicylic acid;   Drug: vitamin K-antagonist
22 Recruiting Aortic Calcification and Vitamin K Antagonists
Condition: Vascular Calcification
Intervention:
23 Not yet recruiting Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.
Condition: Significant Bleeding Risk
Interventions: Drug: Octaplex;   Drug: Beriplex P/N (Kcentra)
24 Unknown  Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream
Condition: Metastatic Colorectal Cancer
Interventions: Device: Reconval K1 Cream;   Device: Reconval Cream
25 Recruiting Pharmacokinetic Drug-Drug Interaction Study of Rucaparib
Condition: Neoplasms
Interventions: Drug: Caffeine;   Drug: Warfarin;   Drug: Omeprazole;   Drug: Midazolam;   Drug: digoxin;   Drug: Vitamin K;   Drug: Rucaparib
26 Recruiting An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding
Condition: Hemorrhage
Interventions: Biological: Kcentra®;   Biological: Plasma
27 Not yet recruiting Oral Anticoagulation in Haemodialysis Patients
Condition: Kidney Failure, Chronic
Interventions: Biological: No oral anticoagulation, and no monitoring of the INR.;   Drug: Oral anticoagulation with vitamin K antagonists
28 Not yet recruiting Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Condition: Atrial Fibrillation
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Vitamin K antagonists;   Drug: dabigatran (Pradaxa)
29 Unknown  Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists
Conditions: Severe Bleeding;   Urgent Surgery
Intervention:
30 Not yet recruiting Tecarfarin Anti-Coagulation Trial (TACT)
Conditions: Thromboembolism;   Thrombosis
Interventions: Drug: Warfarin;   Drug: tecarfarin
31 Not yet recruiting COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials
Conditions: Stable Angina;   Unstable Angina;   STEMI;   NSTEMI;   Coronary Disease
Interventions: Device: COMBO-Stent;   Drug: Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran;   Device: Any drug eluting stent oder bare metal sent;   Drug: ASA, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran
32 Recruiting Novel Oral Anticoagulants in Stroke Patients
Conditions: Ischemic Stroke,;   Intracranial Hemorrhage,
Intervention:
33 Recruiting Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients
Condition: Unsuspected Pulmonary Embolism
Intervention: Drug: Heparin, fondaparinux, vitamin-K antagonists, aspirin
34 Unknown  Anti Vitamin K Therapeutic Education
Condition: Cardio-vascular Diseases
Intervention: Other: therapeutic education program
35 Recruiting Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification
Conditions: Atrial Fibrillation or Pulmonary Embolism;   Need of Long Term Oral Anticoagulation Therapy (OAT);   Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location
Intervention: Drug: Rivaroxaban or Marcumar
36 Not yet recruiting INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority
Condition: Rheumatic Heart Disease
Interventions: Drug: Rivaroxaban (15 mg);   Drug: Aspirin
37 Recruiting PREVACT : Preventive REversal of Vitamine K Antagonist in Minor Craniocerebral Trauma
Conditions: Coagulation; Intravascular;   Craniocerebral Trauma;   Haemorrhage
Intervention: Procedure: Reversion
38 Not yet recruiting Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 75 Years and Over Suffering From Non Valvular Atrial Fibrillation (nv AF)
Condition: Non Valvular Atrial Fibrillation (nv AF)
Interventions: Drug: Non-exposed group;   Drug: Exposed group
39 Recruiting Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation
Conditions: Permanent Atrial Fibrillation;   Venous Thrombosis;   Pulmonary Embolism;   Anticoagulation Treatment at Least > or = to 12-month
Interventions: Drug: Rivaroxaban;   Drug: Fluindione;   Drug: Warfarin
40 Recruiting RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Condition: Venous Thromboembolism
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years